Lactate-Mediated Ran Lactylation: A New Mechanism for Astrocyte Polarization After Spinal Cord Injury

Study Background and Research Question

Secondary damage after spinal cord injury (SCI) is characterized by inflammation, disruption of the blood-spinal cord barrier (BSCB), and scar formation, leading to significant and often irreversible neurological deficits. Astrocytes, as the most abundant glial cells in the central nervous system (CNS), play a critical role in restricting lesion expansion and facilitating tissue repair by proliferating and migrating to the injury site. Their functional polarization into neuroprotective (A2) or neurotoxic (A1) subtypes directly influences neurological outcomes. While lactate was long considered a metabolic by-product, emerging evidence indicates it can modulate neuroinflammatory responses and axonal regeneration. However, the precise molecular mechanisms by which lactate influences astrocyte polarization, particularly through post-translational protein modifications, remained unclear until recently.

Key Innovation from the Reference Study

The reference study (International Immunopharmacology, 2026) provides the first detailed mechanistic evidence that lactate accumulation after SCI promotes astrocyte polarization through SIRT1-regulated lactylation of the non-histone Ran GTPase at lysine 123 (K123). This lactylation event facilitates the nuclear transport of STAT3, a master regulator of astrocyte activation and function, thus linking metabolic changes to epigenetic regulation of CNS repair processes. The identification of Ran K123 lactylation as a crucial node in this pathway represents a significant advance in understanding how metabolic-epigenetic crosstalk governs glial responses to injury.

Methods and Experimental Design Insights

The study employed both in vitro and in vivo models to dissect the role of lactate and SIRT1 in astrocyte polarization following oxygen-glucose deprivation/reoxygenation (OGD/R), which mimics ischemic/hypoxic conditions encountered during SCI. Key experimental approaches included:

• Manipulation of lactate levels: Sodium lactate was used to elevate, and sodium oxamate to reduce, intracellular lactate in cultured astrocytes and animal models.
• Assessment of astrocyte phenotype: Polarization was evaluated by analyzing proliferation, migration, and the expression of A2 (neuroprotective) versus A1 (neurotoxic) markers.
• Lactylome profiling: Mass spectrometry-based proteomics identified lactylated proteins, pinpointing non-histone Ran as a key target at K123.
• Genetic manipulation: Short hairpin RNA (shRNA) knockdown and K123 mutation of Ran were used to probe causality in the lactylation-dependent pathway.
• SIRT1 functional analysis: Pharmacological inhibition and genetic silencing of SIRT1 were employed to establish its regulatory role in Ran lactylation.
• STAT3 nuclear transport assays: Subcellular fractionation and immunofluorescence tracked STAT3 localization in response to experimental manipulations.

These complementary techniques provided robust evidence for the involvement of a SIRT1–Ran–STAT3 axis in lactate-induced astrocyte polarization.

Core Findings and Why They Matter

The study demonstrates several critical points:

• Lactate promotes astrocyte proliferation, migration, and A2 polarization after OGD/R, both in cell culture and in SCI animal models (reference study).
• STAT3 nuclear translocation is essential for lactate-driven astrocyte polarization. Inhibition of STAT3 nuclear transport abrogates lactate’s effects, confirming its central role.
• Non-histone Ran GTPase is a direct target of lactylation at lysine 123 (K123). Lactylome analysis and mutational studies show that K123 lactylation is required for STAT3 nuclear import and subsequent astrocyte polarization.
• SIRT1 is a key regulator of Ran K123 lactylation. Loss of SIRT1 function reduces Ran lactylation and impairs lactate-induced STAT3 nuclear translocation, establishing a direct metabolic–epigenetic–signaling link.

These findings reveal a new metabolic-epigenetic axis involving SIRT1-mediated regulation of non-histone protein lactylation as a driver of astrocyte functional responses after CNS injury. This mechanism provides a foundation for novel therapeutic targets to promote neuroprotection and repair by modulating glial cell fate.

Comparison with Existing Internal Articles

Several recent internal resources have highlighted the utility of SIRT1/2 inhibitors in dissecting metabolic and epigenetic mechanisms within both cancer and CNS injury models. For example, "SIRT1/2 Inhibitor IV (cambinol): Applied CNS and Tumor Workflows" and "SIRT1/2 Inhibitor IV (cambinol): Protocols for CNS & Cancer Research" discuss how SIRT1/2 Inhibitor IV (cambinol) can be leveraged to manipulate SIRT1-regulated post-translational modifications, including non-histone lactylation, in both tumor and CNS models. These articles, together with the new reference study, support the concept that targeted SIRT inhibition can clarify the role of metabolic intermediates like lactate in regulating cell fate through epigenetic processes. Notably, the internal article "Lactate-Induced Ran Lactylation Regulates Astrocyte Polarization via SIRT1" provides an accessible summary of the same core findings, further underscoring the translational potential of SIRT1/2 inhibition in CNS repair.

Protocol Parameters

• OGD/R induction: Expose cultured astrocytes to oxygen-glucose deprivation for 4 hours followed by reoxygenation for 24 hours to mimic SCI conditions (as described in the reference study).
• Lactate manipulation: Treat with 10–20 mM sodium lactate to increase intracellular lactate; use 20 mM sodium oxamate to decrease lactate levels.
• SIRT1 inhibition: Pharmacological inhibition of SIRT1 (e.g., with cambinol or similar SIRT1/2 inhibitors) at concentrations of 10–40 µM in vitro, or via in vivo dosing as per published protocols.
• Ran functional assays: Use shRNA-mediated knockdown or K123R mutation to disrupt lactylation at the identified site.
• Phenotypic readouts: Assess astrocyte polarization by GFAP, S100A10 (A2 marker), and C3 (A1 marker) expression, as well as migration and proliferation assays.

Note: Parameter values are based on representative protocols from the reference paper and related internal articles. Researchers should optimize conditions for their experimental systems.

Limitations and Transferability

The study's main limitation is its focus on acute injury models and rodent systems, which may not fully recapitulate the complexity of human CNS injury. While the evidence for SIRT1-mediated Ran lactylation is compelling in both in vitro and in vivo models, further research is needed to determine the relevance of this pathway in chronic injury, disease states, and across different species. In addition, off-target effects and compensatory mechanisms may influence the outcome of SIRT1/2 inhibition in vivo.

Research Support Resources

Researchers aiming to dissect the role of SIRT1-regulated lactylation in astrocyte polarization can utilize SIRT1/2 Inhibitor IV (cambinol) (SKU B6063) as a small-molecule tool to selectively inhibit SIRT1/2 activity in both cell-based and animal models. According to the product information, cambinol is cell-permeable and has been validated for effective SIRT1 and SIRT2 inhibition in diverse biological contexts, including the study of protein acetylation and lactylation. For detailed protocols and further workflow guidance, consult internal resources such as "SIRT1/2 Inhibitor IV (cambinol): CNS & Tumor Protocol Innovations". As always, SIRT1/2 Inhibitor IV is intended for scientific research use only and should be handled according to recommended safety and storage guidelines.